Search

Your search keyword '"Grimmelmann, Imke"' showing total 22 results
Start Over Author "Grimmelmann, Imke"
22 results on '"Grimmelmann, Imke"'

1. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Author

van Akkooi, Alexander, van Houdt, Winan, Wilhelm, Tabea, Farmer, Kimberley, Ulrich, Claas, Gambichler, Thilo, Bluhm, Leonie, Schinagl, Heidemarie, Kellner, Ivonne, Herbst, Rudolf, Meiß, Frank, Rafei-Shamsabadi, David, Sell, Sabine, Kaatz, Martin, Wulfken, Lena, Hartmann, Martin, Kähler, Katharina, Ziemer, Mirjana, Simon, Jan, Terheyden, Patrick, Thaci, Diamant, Loquai, Carmen, Mitzel-Rink, Heidrun, Grabbe, Stephan, Stege, Henner, Gaiser, Maria, Utikal, Jochen, Berking, Carola, Heinzerling, Lucie, Schlaak, Max, Tomsitz, Dirk, Dyballa, Jörg, Magnolo, Nina, Weishaupt, Carsten, Berneburg, Mark, Garbe, Claus, Flatz, Lukas, Gesierich, Anja, Schilling, Bastian, Becker, Jürgen C, Ugurel, Selma, Leiter, Ulrike, Meier, Friedegund, Gutzmer, Ralf, Haferkamp, Sebastian, Zimmer, Lisa, Livingstone, Elisabeth, Eigentler, Thomas K, Hauschild, Axel, Kiecker, Felix, Hassel, Jessica C, Mohr, Peter, Fluck, Michael, Thomas, Ioannis, Garzarolli, Marlene, Grimmelmann, Imke, Drexler, Konstantin, Spillner, Alexandra N, Eckhardt, Sebastian, and Schadendorf, Dirk

Published
2023
Full Text
View/download PDF

4. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Author

Becker, Jürgen C, primary, Ugurel, Selma, additional, Leiter, Ulrike, additional, Meier, Friedegund, additional, Gutzmer, Ralf, additional, Haferkamp, Sebastian, additional, Zimmer, Lisa, additional, Livingstone, Elisabeth, additional, Eigentler, Thomas K, additional, Hauschild, Axel, additional, Kiecker, Felix, additional, Hassel, Jessica C, additional, Mohr, Peter, additional, Fluck, Michael, additional, Thomas, Ioannis, additional, Garzarolli, Marlene, additional, Grimmelmann, Imke, additional, Drexler, Konstantin, additional, Spillner, Alexandra N, additional, Eckhardt, Sebastian, additional, Schadendorf, Dirk, additional, van Akkoi, Alexander, additional, van Houdt, Winan, additional, Wilhelm, Tabea, additional, Farmer, Kimberly, additional, Ulrich, Claas, additional, Gambichler, Thilo, additional, Bluhm, Leonie, additional, Schinagl, Heidemarie, additional, Kellner, Ivonne, additional, Herbst, Rudolf, additional, Meiß, Frank, additional, Rafei-Shamsabadi, David, additional, Sell, Sabine, additional, Kaatz, Martin, additional, Wulfken, Lena, additional, Hartmann, Martin, additional, Kähler, Katharina, additional, Ziemer, Mirjana, additional, Simon, Jan, additional, Terheyden, Patrick, additional, Thaci, Diamant, additional, Loquai, Carmen, additional, Mitzel-Rink, Heidrun, additional, Grabbe, Stephan, additional, Stege, Henner, additional, Gaiser, Maria, additional, Utikal, Jochen, additional, Berking, Carola, additional, Heinzerling, Lucie, additional, Schlaak, Max, additional, Tomsitz, Dirk, additional, Dyballa, Jörg, additional, Magnolo, Nina, additional, Weishaupt, Carsten, additional, Berneburg, Mark, additional, Garbe, Claus, additional, Flatz, Lukas, additional, Gesierich, Anja, additional, and Schilling, Bastian, additional

Published
2023
Full Text
View/download PDF

5. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

Author

Franklin, Cindy, primary, Mohr, Peter, additional, Bluhm, Leonie, additional, Meier, Friedegund, additional, Garzarolli, Marlene, additional, Weichenthal, Michael, additional, Kähler, Katharina, additional, Grimmelmann, Imke, additional, Gutzmer, Ralf, additional, Utikal, Jochen, additional, Terheyden, Patrick, additional, Herbst, Rudolf, additional, Haferkamp, Sebastian, additional, Pfoehler, Claudia, additional, Forschner, Andrea, additional, Leiter, Ulrike, additional, Ziller, Fabian, additional, Meiss, Frank, additional, Ulrich, Jens, additional, Kreuter, Alexander, additional, Gebhardt, Christoffer, additional, Welzel, Julia, additional, Schilling, Bastian, additional, Kaatz, Martin, additional, Scharfetter-Kochanek, Karin, additional, Dippel, Edgar, additional, Nashan, Dorothee, additional, Sachse, Michael, additional, Weishaupt, Carsten, additional, Löffler, Harald, additional, Gambichler, Thilo, additional, Loquai, Carmen, additional, Heinzerling, Lucie, additional, Grabbe, Stephan, additional, Debus, Dirk, additional, Schley, Gaston, additional, Hassel, Jessica C, additional, Weyandt, Gerhard, additional, Trommer, Maike, additional, Lodde, Georg, additional, Placke, Jan-Malte, additional, Zimmer, Lisa, additional, Livingstone, Elisabeth, additional, Becker, Jürgen Christian, additional, Horn, Susanne, additional, Schadendorf, Dirk, additional, and Ugurel, Selma, additional

Published
2023
Full Text
View/download PDF

6. Immune checkpoint inhibition and targeted therapy for melanoma: A patient‐oriented cross‐sectional comparative multicentre study

Author

Thiem, Alexander, primary, Mashhadiakbar, Pegah, additional, Cussigh, Christiane, additional, Hassel, Jessica C., additional, Grimmelmann, Imke, additional, Gutzmer, Ralf, additional, Schlaak, Max, additional, Heppt, Markus V., additional, Dücker, Pia, additional, Hüning, Svea, additional, Schulmeyer, Lena, additional, Schilling, Bastian, additional, Haferkamp, Sebastian, additional, Ziemer, Mirjana, additional, Moritz, Rose K. C., additional, Hagelstein, Victoria, additional, Terheyden, Patrick, additional, Posch, Christian, additional, Gaiser, Maria R., additional, Kropp, Peter, additional, Emmert, Steffen, additional, Müller, Britta, additional, and Tietze, Julia K., additional

Published
2022
Full Text
View/download PDF

7. Hauterkrankungen ganzheitlich repräsentiert – ein Seminar des Wissenschaftsmoduls an der Medizinischen Hochschule Hannover (MHH)

Author

Karmann, Naomi, Mikuteit, Marie, Kocyigit, Merve, Mbang Springer, Daliah Laura, Grimmelmann, Imke, Paulmann, Volker, and Steffens, Sandra

Subjects
Medicine and health
Abstract

Fragestellung/Zielsetzung: Aktuell wird im Rahmen des Wissenschaftsmoduls an der MHH ein Seminar mit dem Titel „Hauterkrankungen ganzheitlich repräsentiert“ konzipiert. Hintergrund dessen ist die mangelnde Repräsentation von Körpern mit unterschiedlicher Hautfarbe in [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

8. Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients

Author

DeTemple, Viola K., primary, Hassel, Jessica C., additional, Sachse, Michael M., additional, Grimmelmann, Imke, additional, Leiter, Ulrike, additional, Gebhardt, Christoffer, additional, Eckardt, Julia, additional, Pföhler, Claudia, additional, Angela, Yenny, additional, Hübbe, Hanna, additional, and Gutzmer, Ralf, additional

Published
2022
Full Text
View/download PDF

9. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG

Author

Franklin, Cindy, primary, Mohr, Peter, additional, Bluhm, Leonie, additional, Grimmelmann, Imke, additional, Gutzmer, Ralf, additional, Meier, Friedegund, additional, Garzarolli, Marlene, additional, Weichenthal, Michael, additional, Pfoehler, Claudia, additional, Herbst, Rudolf, additional, Terheyden, Patrick, additional, Utikal, Jochen, additional, Ulrich, Jens, additional, Debus, Dirk, additional, Haferkamp, Sebastian, additional, Kaatz, Martin, additional, Forschner, Andrea, additional, Leiter, Ulrike, additional, Nashan, Dorothee, additional, Kreuter, Alexander, additional, Sachse, Michael, additional, Welzel, Julia, additional, Heinzerling, Lucie, additional, Meiss, Frank, additional, Weishaupt, Carsten, additional, Gambichler, Thilo, additional, Weyandt, Gerhard, additional, Dippel, Edgar, additional, Schatton, Kerstin, additional, Celik, Eren, additional, Trommer, Maike, additional, Helfrich, Iris, additional, Roesch, Alexander, additional, Zimmer, Lisa, additional, Livingstone, Elisabeth, additional, Schadendorf, Dirk, additional, Horn, Susanne, additional, and Ugurel, Selma, additional

Published
2022
Full Text
View/download PDF

10. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG

Author

Franklin, Cindy, Mohr, Peter, Bluhm, Leonie, Grimmelmann, Imke, Gutzmer, Ralf, Meier, Friedegund, Garzarolli, Marlene, Weichenthal, Michael, Pfoehler, Claudia, Herbst, Rudolf, Terheyden, Patrick, Utikal, Jochen, Ulrich, Jens, Debus, Dirk, Haferkamp, Sebastian, Kaatz, Martin, Forschner, Andrea, Leiter, Ulrike, Nashan, Dorothee, Kreuter, Alexander, Sachse, Michael, Welzel, Julia, Heinzerling, Lucie, Meiss, Frank, Weishaupt, Carsten, Gambichler, Thilo, Weyandt, Gerhard, Dippel, Edgar, Schatton, Kerstin, Celik, Eren, Trommer, Maike, Helfrich, Iris, Roesch, Alexander, Zimmer, Lisa, Livingstone, Elisabeth, Schadendorf, Dirk, Horn, Susanne, Ugurel, Selma, Franklin, Cindy, Mohr, Peter, Bluhm, Leonie, Grimmelmann, Imke, Gutzmer, Ralf, Meier, Friedegund, Garzarolli, Marlene, Weichenthal, Michael, Pfoehler, Claudia, Herbst, Rudolf, Terheyden, Patrick, Utikal, Jochen, Ulrich, Jens, Debus, Dirk, Haferkamp, Sebastian, Kaatz, Martin, Forschner, Andrea, Leiter, Ulrike, Nashan, Dorothee, Kreuter, Alexander, Sachse, Michael, Welzel, Julia, Heinzerling, Lucie, Meiss, Frank, Weishaupt, Carsten, Gambichler, Thilo, Weyandt, Gerhard, Dippel, Edgar, Schatton, Kerstin, Celik, Eren, Trommer, Maike, Helfrich, Iris, Roesch, Alexander, Zimmer, Lisa, Livingstone, Elisabeth, Schadendorf, Dirk, Horn, Susanne, and Ugurel, Selma

Abstract

Background Despite of various therapeutic strategies, treatment of patients with melanoma brain metastasis (MBM) still is a major challenge. This study aimed at investigating the impact of type and sequence of immune checkpoint blockade (ICB) and targeted therapy (TT), radiotherapy, and surgery on the survival outcome of patients with MBM. Method We assessed data of 450 patients collected within the prospective multicenter real-world skin cancer registry ADOREG who were diagnosed with MBM before start of the first non-adjuvant systemic therapy. Study endpoints were progression-free survival (PFS) and overall survival (OS). Results Of 450 MBM patients, 175 (38.9%) received CTLA-4+PD-1 ICB, 161 (35.8%) PD-1 ICB, and 114 (25.3%) BRAF+MEK TT as first-line treatment. Additional to systemic therapy, 67.3% of the patients received radiotherapy (stereotactic radiosurgery (SRS); conventional radiotherapy (CRT)) and 24.4% had surgery of MBM. 199 patients (42.2%) received a second-line systemic therapy. Multivariate Cox regression analysis revealed the application of radiotherapy (HR for SRS: 0.213, 95% CI 0.094 to 0.485, p<0.001; HR for CRT: 0.424, 95% CI 0.210 to 0.855, p=0.016), maximal size of brain metastases (HR for MBM >1 cm: 1.977, 95% CI 1.117 to 3.500, p=0.019), age (HR for age >65 years: 1.802, 95% CI 1.016 to 3.197, p=0.044), and ECOG performance status (HR for ECOG >= 2: HR: 2.615, 95% CI 1.024 to 6.676, p=0.044) as independent prognostic factors of OS on first-line therapy. The type of first-line therapy (ICB vs TT) was not independently prognostic. As second-line therapy BRAF+MEK showed the best survival outcome compared with ICB and other therapies (HR for CTLA-4+PD-1 compared with BRAF+MEK: 13.964, 95% CI 3.6 to 54.4, p<0.001; for PD-1 vs BRAF+MEK: 4.587 95% CI 1.3 to 16.8, p=0.022 for OS). Regarding therapy sequencing, patients treated with ICB as first-line therapy and BRAF+MEK as second-line therapy showed an improved OS (HR for CTLA-4+PD-1 followed by BRAF

Published
2022

11. Immune checkpoint inhibition and targeted therapy for melanoma: A patient‐oriented cross‐sectional comparative multicentre study.

Author

Thiem, Alexander, Mashhadiakbar, Pegah, Cussigh, Christiane, Hassel, Jessica C., Grimmelmann, Imke, Gutzmer, Ralf, Schlaak, Max, Heppt, Markus V., Dücker, Pia, Hüning, Svea, Schulmeyer, Lena, Schilling, Bastian, Haferkamp, Sebastian, Ziemer, Mirjana, Moritz, Rose K. C., Hagelstein, Victoria, Terheyden, Patrick, Posch, Christian, Gaiser, Maria R., and Kropp, Peter

Subjects
IMMUNE checkpoint inhibitors, PATIENTS' attitudes, IPILIMUMAB, SKIN cancer, OLDER patients, MELANOMA, THERAPEUTICS
Abstract

Background: Choosing the adequate systemic treatment for melanoma is driven by clinical parameters and personal preferences. Objective: Evaluation of the impact of disease and treatment on the daily life of patients receiving systemic therapy for melanoma. Methods: A German‐wide, cross‐sectional comparative study was conducted at 13 specialized skin cancer centres from 08/2020 to 03/2021. A questionnaire was distributed to assess patients' perception of disease and symptoms, the impact of their current treatment on quality of life (QOL) and activities, adverse events (AEs), therapeutic visits, as well as believe in and satisfaction with their current systemic melanoma treatment. Patient‐reported outcomes (PROs) were rated on a continuous numerical rating scale or selected from a given list. Results: Four hundred and fourteen patients with systemic melanoma therapy were included. 359 (87%) received immune checkpoint inhibition (ICI) and 55 (13%) targeted therapy (TT). About 1/3 of patients were adjuvantly treated, the remaining because of unresectable/metastatic melanoma. In subgroup analyses, only in the adjuvant setting, TT patients reported a significant decrease in their treatment associated QOL compared to patients with ICI (p = 0.02). Patients with TT were 1.9 times more likely to report AEs than patients with ICI, a difference being significant just for the adjuvant setting (p = 0.01). ICI treatment intervals differed significantly between adjuvant and unresectable/metastatic setting (p = 0.04), though all patients, regardless of their specific ICI drug, evaluated their treatment frequency as adequate. TT patients with dabrafenib/trametinib (n = 37) or encorafenib/binimetinib (n = 15) did not differ regarding the strain of daily pill intake. Patients older than 63 years rated various PROs better than younger patients. Conclusions: Patients evaluated their treatment mainly positively. ICI might be preferred over TT regarding QOL and patient‐reported AEs in the adjuvant setting. Older melanoma patients appeared to be less impacted by their disease and more satisfied with their treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor‐associated neurotoxicity.

Author

Möhn, Nora, Mahjoub, Susann, Duzzi, Laura, Narten, Emily, Grote‐Levi, Lea, Körner, Gudrun, Seeliger, Tabea, Beutel, Gernot, Bollmann, Benjamin‐Alexander, Wirth, Thomas, Huss, André, Tumani, Hayrettin, Grimmelmann, Imke, Gutzmer, Ralf, Ivanyi, Philipp, and Skripuletz, Thomas

Subjects
MONOCYTE chemotactic factor, IMMUNE checkpoint proteins, DRUG side effects, IPILIMUMAB, BRAIN-derived neurotrophic factor, IMMUNE checkpoint inhibitors, MONOCLONAL gammopathies
Abstract

Background: Oncological patients can benefit substantially from treatment with immune checkpoint inhibitors (ICI). However, there is a growing awareness of immune‐related adverse events (irAE). Especially ICI‐mediated neurological adverse events (nAE(+)), are tough to diagnose and biomarkers to identify patients at risk are missing. Methods: A prospective register with prespecified examinations was established for ICI treated patients in December 2019. At the time of data cut‐off, 110 patients were enrolled and completed the clinical protocol. Herein, cytokines and serum neurofilament light chain (sNFL) from 21 patients were analyzed. Results: nAE of any grade were observed in 31% of the patients (n = 34/110). In nAE(+) patients a significant increase in sNFL concentrations over time was observed. Patients with higher‐grade nAE had significantly elevated serum‐concentrations of monocyte chemoattractant protein 1 (MCP‐1) and brain‐derived neurotrophic factor (BDNF) at baseline compared to individuals without any nAE (p < 0.01 and p < 0.05). Conclusion: Here, we identified nAE to occur more frequently than previously reported. Increase of sNFL during nAE confirms the clinical diagnosis of neurotoxicity and might be a suitable marker for neuronal damage associated with ICI therapy. Furthermore, MCP‐1 and BDNF are potentially the first clinical‐class nAE predictors for patients under ICI therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – An evaluation of the multicenter prospective skin cancer registry ADOREG

Author

Kreft, Sophia, primary, Glutsch, Valerie, additional, Zaremba, Anne, additional, Schummer, Patrick, additional, Mohr, Peter, additional, Grimmelmann, Imke, additional, Gutzmer, Ralf, additional, Meier, Friedegund, additional, Pföhler, Claudia, additional, Sachse, Michael Max, additional, Meiss, Frank, additional, Forschner, Andrea, additional, Haferkamp, Sebastian, additional, Welzel, Julia, additional, Terheyden, Patrick, additional, Herbst, Rudolf, additional, Utikal, Jochen, additional, Kaatz, Martin, additional, Weishaupt, Carsten, additional, Kreuter, Alexander, additional, Debus, Dirk, additional, Duecker, Pia, additional, Sindrilaru, Anca, additional, Löffler, Harald, additional, Schley, Gaston, additional, Weichenthal, Michael, additional, Schadendorf, Dirk, additional, Ugurel, Selma, additional, Gesierich, Anja, additional, and Schilling, Bastian, additional

Published
2022
Full Text
View/download PDF

14. Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

Author

Mohr, Peter, primary, Scherrer, Emilie, additional, Assaf, Chalid, additional, Bender, Marc, additional, Berking, Carola, additional, Chandwani, Sheenu, additional, Eigentler, Thomas, additional, Grimmelmann, Imke, additional, Gutzmer, Ralf, additional, Haferkamp, Sebastian, additional, Hassel, Jessica, additional, Hauschild, Axel, additional, Herbst, Rudolf, additional, Jiang, Ruixuan, additional, Kähler, Katharina, additional, Krepler, Clemens, additional, Kreuter, Alexander, additional, Leiter, Ulrike, additional, Loquai, Carmen, additional, Meier, Friedegund, additional, Pföhler, Claudia, additional, Rudolph, Anja, additional, Schadendorf, Dirk, additional, Schiavone, Maximo, additional, Schley, Gaston, additional, Terheyden, Patrick, additional, Ugurel, Selma, additional, Ulrich, Jens, additional, Utikal, Jochen, additional, Weishaupt, Carsten, additional, Welzel, Julia, additional, and Weichenthal, Michael, additional

Published
2022
Full Text
View/download PDF

15. Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade

Author

Niewolik, Jacqueline, primary, Mikuteit, Marie, additional, Cossmann, Anne, additional, Vahldiek, Kai, additional, Gutzmer, Ralf, additional, Müller, Frank, additional, Schröder, Dominik, additional, Heinemann, Stephanie, additional, Behrens, Georg M.N., additional, Dopfer-Jablonka, Alexandra, additional, Steffens, Sandra, additional, and Grimmelmann, Imke, additional

Published
2022
Full Text
View/download PDF

19. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group

Author

Grimmelmann, Imke, primary, Momma, Michael, additional, Zimmer, Lisa, additional, Hassel, Jessica C., additional, Heinzerling, Lucie, additional, Pföhler, Claudia, additional, Loquai, Carmen, additional, Ruini, Cristel, additional, Utikal, Jochen, additional, Thoms, Kai-Martin, additional, Kähler, Katharina C., additional, Eigentler, Thomas, additional, Herbst, Rudolf A., additional, Meier, Friedegund, additional, Debus, Dirk, additional, Berking, Carola, additional, Kochanek, Corinna, additional, Ugurel, Selma, additional, and Gutzmer, Ralf, additional

Published
2021
Full Text
View/download PDF

22. Psoriasis vulgaris triggered by treatment with mogamulizumab in a patient with cutaneous T-cell lymphoma.

Author

Lehner GM, Schacht V, Angela Y, Grimmelmann I, and Gutzmer R

Subjects
Antibodies, Monoclonal, Humanized, Humans, Neoplasm Recurrence, Local, Lymphoma, T-Cell, Cutaneous chemically induced, Lymphoma, T-Cell, Cutaneous diagnosis, Lymphoma, T-Cell, Cutaneous drug therapy, Psoriasis chemically induced, Psoriasis diagnosis, Psoriasis drug therapy, Skin Neoplasms chemically induced, Skin Neoplasms drug therapy
Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results